Logo Fortrea

Fortrea (FTRE) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Fortrea · Health Care · ref. ETF XLV · 52 calls · price $18.86
🏆JPI 2026 portfoliosSee tracking →
What the company does: Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

📈 Fortrea (FTRE) stock price

$18.86+95.4% over range
Aug 28, 25low $8.4 · high $20.7Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
67% recommend buying · 6 analysts
📊 JPI status : Fortrea has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 FTRE price target & analyst consensusprice $18.86

The price target · all analysts combined (7 targets)
Highest target · 1 firm of 7$26+37.9%
Median target · of 7 targets$22.5+19.3%
Lowest target · 2 firms of 7$16-15.2%
Current price$18.86
Where these 7 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 571% $22 ↔ $26
Below 229% $16
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

The consensus · 6 ratings (last 6 months)
Strong Buy00%
Buy467%
Hold233%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Fortrea? The JPI assistant answers using our backtest data.

🔎 Detailed analyses

✅ Historical analyst reliability on FTRE

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
B of A Securities  100% +63.7% 5
Baird  20% -11.0% 5
Citigroup  0% -48.5% 2
Evercore ISI Group  0% -56.8% 2
Barclays  0% -101.1% 5

📊 What $1,000 invested in Fortrea would be worth › open the full page

In short — $1,000 invested in Fortrea 10 years ago would be worth $599 today, i.e. -16%/yr on average. Best year: 2025 (-13%), worst: 2024 (-45%). Price performance, excluding dividends.

If I'd invested $1,000 in Fortrea

InvestmentWorth todayGain
1 years ago$935-6%
3 years ago$599-40%
→ See Fortrea's full return history + gain calculator

Return by year (Fortrea)

YearReturn$1,000 invested at year start
2026 (YTD)+7%$1,073 (+7%)
2025-13%$935 (-6%)
2024-45%$517 (-48%)
→ See Fortrea's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Fortrea

Loading news…

📋 All analyst calls on FTRE

TD Cowen 
Aug 4, 26
▲ Buy · 🎯$23
Price at call : $19.05 — upside +21%
Today : $18.86 — upside +22%
🎯 on FTRE : no call matured yet · 📊 on Health : 55.3% · -0.8% (38 calls)
in progress (365j)
matures : Aug 4, 27
Citigroup 
Jul 31, 26
▲ Buy · 🎯$22
Price at call : $18.94 — upside +16%
Today : $18.86 — upside +17%
🎯 on FTRE : no call matured yet · 📊 on Health : 43.8% · -5.4% (105 calls)
in progress (365j)
matures : Jul 31, 27
▲ Buy · 🎯$26
Price at call : $19.17 — upside +36%
Today : $18.86 — upside +38%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.6% · -0.8% (165 calls)
in progress (365j)
matures : Jul 30, 27
▲ Outperform · 🎯$25
Price at call : $19.17 — upside +30%
Today : $18.86 — upside +33%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Jul 30, 27
Barclays 
Jul 30, 26
■ Equal-Weight neutral · not a buy · 🎯$22
Price at call : $19.08 — gap to target +15%
Today : $18.86 — gap to target +17%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Jul 30, 27
Mizuho 
Jul 13, 26
■ Neutral neutral · not a buy · 🎯$16
Price at call : $17.86 — gap to target -10%
Today : $18.86 — gap to target -15%
🎯 on FTRE : no call matured yet · 📊 on Health : 26.4% · -9.4% (87 calls)
in progress (365j)
matures : Jul 13, 27
Barclays 
Jun 24, 26
■ Equal-Weight neutral · not a buy · 🎯$18
Price at call : $17.02 — gap to target +6%
Today : $18.86 — gap to target -5%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Jun 24, 27
Mizuho 
May 12, 26
■ Neutral neutral · not a buy · 🎯$13
Price at call : $14.61 — gap to target -11%
Today : $18.86 — gap to target -31%
🎯 on FTRE : no call matured yet · 📊 on Health : 26.4% · -9.4% (87 calls)
in progress (365j)
matures : May 12, 27
See the other 44 calls, newest to oldest
Citigroup 
May 6, 26
▲ Buy · 🎯$20
Price at call : $15.57 — upside +28%
Today : $18.86 — upside +6%
🎯 on FTRE : no call matured yet · 📊 on Health : 43.8% · -5.4% (105 calls)
in progress (365j)
matures : May 6, 27
Barclays 
May 6, 26
■ Equal-Weight neutral · not a buy · 🎯$16
Price at call : $15.57 — gap to target +3%
Today : $18.86 — gap to target -15%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : May 6, 27
Barclays 
Apr 14, 26
■ Equal-Weight neutral · not a buy · 🎯$11
Price at call : $10.05 — gap to target +9%
Today : $18.86 — gap to target -42%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Apr 14, 27
▲ Outperform · 🎯$14
Price at call : $9.38 — upside +49%
Today : $18.86 — upside -26%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Apr 8, 27
TD Cowen 
Mar 9, 26
▲ Buy · 🎯$15
Price at call : $8.95 — upside +68%
Today : $18.86 — upside -20%
🎯 on FTRE : no call matured yet · 📊 on Health : 55.3% · -0.8% (38 calls)
in progress (365j)
matures : Mar 9, 27
Barclays 
Feb 27, 26
■ Equal-Weight neutral · not a buy · 🎯$12
Price at call : $10.56 — gap to target +14%
Today : $18.86 — gap to target -36%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Feb 27, 27
Baird 
Feb 27, 26
▲ Outperform · 🎯$16
Price at call : $10.72 — upside +49%
Today : $18.86 — upside -15%
🎯 on FTRE : 33% (3 calls matureds) · 📊 on Health : 37.8% · -2.8% (82 calls)
in progress (365j)
matures : Feb 27, 27
TD Cowen 
Jan 22, 26
■ Hold neutral · not a buy · 🎯$15
Price at call : $16.83 — gap to target -11%
Today : $18.86 — gap to target -20%
🎯 on FTRE : no call matured yet · 📊 on Health : 55.3% · -0.8% (38 calls)
in progress (365j)
matures : Jan 22, 27
▲ Buy · 🎯$22
Price at call : $17.44 — upside +26%
Today : $18.86 — upside +17%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.6% · -0.8% (165 calls)
in progress (365j)
matures : Jan 8, 27
▲ Outperform · 🎯$25
Price at call : $17.49 — upside +43%
Today : $18.86 — upside +33%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Jan 6, 27
Mizuho 
Dec 18, 25
■ Neutral neutral · not a buy · 🎯$13
Price at call : $16.61 — gap to target -22%
Today : $18.86 — gap to target -31%
🎯 on FTRE : no call matured yet · 📊 on Health : 26.4% · -9.4% (87 calls)
in progress (365j)
matures : Dec 18, 26
Barclays 
Dec 15, 25
■ Equal-Weight neutral · not a buy · 🎯$15
Price at call : $16.06 — gap to target -7%
Today : $18.86 — gap to target -20%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Dec 15, 26
Citigroup 
Dec 11, 25
▲ Buy · 🎯$21
Price at call : $15.55 — upside +35%
Today : $18.86 — upside +11%
🎯 on FTRE : no call matured yet · 📊 on Health : 43.8% · -5.4% (105 calls)
in progress (365j)
matures : Dec 11, 26
Barclays 
Nov 6, 25
▼ Underweight · 🎯$10
Price at call : $11.25 — upside -11%
Today : $18.86 — upside -47%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Nov 6, 26
Mizuho 
Oct 17, 25
■ Neutral neutral · not a buy · 🎯$9
Price at call : $9.45 — gap to target -5%
Today : $18.86 — gap to target -52%
🎯 on FTRE : no call matured yet · 📊 on Health : 26.4% · -9.4% (87 calls)
in progress (365j)
matures : Oct 17, 26
■ In-Line neutral · not a buy · 🎯$11
Price at call : $10.13 — gap to target +9%
Today : $18.86 — gap to target -42%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Oct 8, 26
Barclays 
Oct 2, 25
▼ Underweight · 🎯$8
Price at call : $9.45 — upside -15%
Today : $18.86 — upside -58%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Oct 2, 26
Jefferies 
Sep 9, 25
■ Hold neutral · not a buy · 🎯$9.5
Price at call : $10.07 — gap to target -6%
Today : $18.86 — gap to target -50%
🎯 on FTRE : no call matured yet · 📊 on Health : 50% · +9.9% (136 calls)
in progress (365j)
matures : Sep 9, 26
Baird 
Sep 3, 25
▲ Outperform · 🎯$14
Price at call : $10.69 — upside +31%
Today : $18.86 — upside -26%
🎯 on FTRE : 33% (3 calls matureds) · 📊 on Health : 37.8% · -2.8% (82 calls)
in progress (365j)
matures : Sep 3, 26
■ In-Line neutral · not a buy · 🎯$7
Price at call : $6.58 — gap to target +6%
Today : $18.86 — gap to target -63%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Aug 8, 26
Barclays 
Aug 7, 25
▼ Underweight · 🎯$6
Price at call : $7.24 — upside -17%
Today : $18.86 — upside -68%
Expected -17% · Actual +155% · Reason (≤ −15%) : ✗ No
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-154.6%
stock +155% · XLV +28%
matured Aug 7, 26
Baird 
Aug 4, 25
▲ Outperform · 🎯$9
Price at call : $6.42 — upside +40%
Today : $18.86 — upside -52%
Expected +40% · Actual +180% · Reason (≥ +15%) : ✓ Yes
🎯 on FTRE : 33% (3 calls matureds) · 📊 on Health : 37.8% · -2.8% (82 calls)
+180.2%
stock +180% · XLV +22%
matured Aug 4, 26
Mizuho 
Jul 11, 25
■ Neutral neutral · not a buy · 🎯$7
Price at call : $5.01 — gap to target +40%
Today : $18.86 — gap to target -63%
🎯 on FTRE : no call matured yet · 📊 on Health : 26.4% · -9.4% (87 calls)
in progress (365j)
matures : Jul 11, 26
■ In-Line neutral · not a buy · 🎯$5
Price at call : $5.04 — gap to target -1%
Today : $18.86 — gap to target -73%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Jul 9, 26
Goldman Sachs 
May 14, 25
■ Neutral neutral · not a buy · 🎯$5
Price at call : $4.75 — gap to target +5%
Today : $18.86 — gap to target -73%
🎯 on FTRE : no call matured yet · 📊 on Health : 51% · +5.1% (102 calls)
in progress (365j)
matures : May 14, 26
Mizuho 
May 14, 25
■ Neutral neutral · not a buy · 🎯$8
Price at call : $4.75 — gap to target +68%
Today : $18.86 — gap to target -58%
🎯 on FTRE : no call matured yet · 📊 on Health : 26.4% · -9.4% (87 calls)
in progress (365j)
matures : May 14, 26
Barclays 
May 13, 25
▼ Underweight · 🎯$5
Price at call : $4.78 — upside +5%
Today : $18.86 — upside -73%
Expected +5% · Actual +198% · Reason (≤ −15%) : ✗ No
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-197.9%
stock +198% · XLV +14%
matured May 13, 26
Barclays 
Apr 10, 25
▼ Underweight · 🎯$6
Price at call : $5.21 — upside +15%
Today : $18.86 — upside -68%
Expected +15% · Actual +76% · Reason (≤ −15%) : ✗ No
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-76.2%
stock +76% · XLV +9%
matured Apr 10, 26
Mizuho 
Apr 9, 25
■ Neutral neutral · not a buy · 🎯$10
Price at call : $6.45 — gap to target +55%
Today : $18.86 — gap to target -47%
🎯 on FTRE : no call matured yet · 📊 on Health : 26.4% · -9.4% (87 calls)
in progress (365j)
matures : Apr 9, 26
■ In-Line neutral · not a buy · 🎯$15
Price at call : $10.89 — gap to target +38%
Today : $18.86 — gap to target -20%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Mar 4, 26
Goldman Sachs 
Mar 4, 25
■ Neutral neutral · not a buy · 🎯$11
Price at call : $10.96 — gap to target +0%
Today : $18.86 — gap to target -42%
🎯 on FTRE : no call matured yet · 📊 on Health : 51% · +5.1% (102 calls)
in progress (365j)
matures : Mar 4, 26
Barclays 
Mar 4, 25
■ Equal-Weight neutral · not a buy · 🎯$12
Price at call : $10.96 — gap to target +9%
Today : $18.86 — gap to target -36%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Mar 4, 26
William Blair 
Mar 4, 25
■ Market Perform neutral · not a buy
🎯 on FTRE : no call matured yet · 📊 on Health : 32% · -10.8% (25 calls)
in progress (365j)
matures : Mar 4, 26
Citigroup 
Dec 11, 24
■ Neutral neutral · not a buy · 🎯$23
Price at call : $19.45 — gap to target +18%
Today : $18.86 — gap to target +22%
🎯 on FTRE : no call matured yet · 📊 on Health : 43.8% · -5.4% (105 calls)
in progress (365j)
matures : Dec 11, 25
Baird 
Dec 6, 24
■ Neutral neutral · not a buy · 🎯$25
Price at call : $21.67 — gap to target +15%
Today : $18.86 — gap to target +33%
🎯 on FTRE : 33% (3 calls matureds) · 📊 on Health : 37.8% · -2.8% (82 calls)
in progress (365j)
matures : Dec 6, 25
Baird 
Nov 25, 24
▲ Outperform · 🎯$28
Price at call : $20.89 — upside +34%
Today : $18.86 — upside +48%
Expected +34% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on FTRE : 33% (3 calls matureds) · 📊 on Health : 37.8% · -2.8% (82 calls)
-38.8%
stock -39% · XLV +9%
matured Nov 25, 25
TD Cowen 
Nov 11, 24
■ Hold neutral · not a buy · 🎯$25
Price at call : $21.95 — gap to target +14%
Today : $18.86 — gap to target +33%
🎯 on FTRE : no call matured yet · 📊 on Health : 55.3% · -0.8% (38 calls)
in progress (365j)
matures : Nov 11, 25
Barclays 
Nov 11, 24
■ Equal-Weight neutral · not a buy · 🎯$25
Price at call : $22.75 — gap to target +10%
Today : $18.86 — gap to target +33%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Nov 11, 25
Baird 
Nov 11, 24
▲ Outperform · 🎯$30
Price at call : $22.75 — upside +32%
Today : $18.86 — upside +59%
Expected +32% · Actual -48% · Reason (≥ +15%) : ✗ No
🎯 on FTRE : 33% (3 calls matureds) · 📊 on Health : 37.8% · -2.8% (82 calls)
-48.2%
stock -48% · XLV +1%
matured Nov 11, 25
William Blair 
Nov 8, 24
■ Market Perform neutral · not a buy
🎯 on FTRE : no call matured yet · 📊 on Health : 32% · -10.8% (25 calls)
in progress (365j)
matures : Nov 8, 25
Barclays 
Oct 15, 24
■ Equal-Weight neutral · not a buy · 🎯$20
Price at call : $19.57 — gap to target +2%
Today : $18.86 — gap to target +6%
🎯 on FTRE : 0% (3 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Oct 15, 25
■ In-Line neutral · not a buy · 🎯$20
Price at call : $19.15 — gap to target +4%
Today : $18.86 — gap to target +6%
🎯 on FTRE : no call matured yet · 📊 on Health : 37.9% · -7.6% (29 calls)
in progress (365j)
matures : Oct 8, 25
William Blair 
Sep 11, 24
■ Market Perform neutral · not a buy
🎯 on FTRE : no call matured yet · 📊 on Health : 32% · -10.8% (25 calls)
in progress (365j)
matures : Sep 11, 25
William Blair 
Aug 12, 24
■ Market Perform neutral · not a buy
🎯 on FTRE : no call matured yet · 📊 on Health : 32% · -10.8% (25 calls)
in progress (365j)
matures : Aug 12, 25

Frequently asked questions

Should I buy Fortrea stock?

This isn't buy advice. For Fortrea, the analyst consensus is "Buy", with an average price target of $22.50 (+19% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (5 calls tracked on Fortrea). We show the numbers — you decide.

Is it too late to buy Fortrea? How high can it go?

The most bullish analyst target on Fortrea is $26.00 (+38% above today's price); the average is $22.50. That's the upside they see. Check how reliable those analysts have actually been on Fortrea on our site before trusting it.

Is Fortrea still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 5 analysts have a real record on Fortrea, the best hitting 100% over 5 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Fortrea? The case for and against

The arguments for and against, one by one, from the numbers: why invest in FTRE (and why hesitate).

What has Fortrea's past performance been?

Historical returns and a "how much if I had invested" calculator: FTRE performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)